Search

Your search keyword '"Takimoto, Hidetaka"' showing total 7 results
Start Over Author "Takimoto, Hidetaka" Language english
7 results on '"Takimoto, Hidetaka"'

1. Long-term outcomes of patients with primary intestinal follicular lymphoma managed with watch-and-wait strategy

Author

Iwamuro, Masaya, Tanaka, Takehiro, Ennishi, Daisuke, Matsueda, Kazuhiro, Yoshioka, Masao, Miyahara, Koji, Sakaguchi, Chihiro, Nishimura, Mamoru, Nagahara, Teruya, Mannami, Tomohiko, Takenaka, Ryuta, Oka, Shohei, Inoue, Masafumi, Takimoto, Hidetaka, Inaba, Tomoki, Kobayashi, Sayo, Toyokawa, Tatsuya, Tsugeno, Hirofumi, Suzuki, Seiyuu, Sawada, Sachiko, Tanaka, Shouichi, Tsuzuki, Takao, and Okada, Hiroyuki

Published
2023
Full Text
View/download PDF

2. The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Japanese patients with diffuse large B-cell lymphoma: a propensity score matching analysis

Author

Nishimori, Hisakazu, Matsuo, Keitaro, Maeda, Yoshinobu, Nawa, Yuichiro, Sunami, Kazutaka, Togitani, Kazuto, Takimoto, Hidetaka, Hiramatsu, Yasushi, Kiguchi, Toru, Yano, Tomofumi, Yamane, Hiromichi, Tabayashi, Takayuki, Takeuchi, Makoto, Makita, Masanori, Sezaki, Nobuo, Yamasuji, Yoshiko, Sugiyama, Haruko, Tabuchi, Takahiro, Kataoka, Itaru, Fujii, Nobuharu, Ishimaru, Fumihiko, Shinagawa, Katsuji, Ikeda, Kazuma, Hara, Masamichi, Yoshino, Tadashi, Tanimoto, Mitsune, and for the West-Japan Hematology and Oncology Group (West-JHOG)

Published
2009
Full Text
View/download PDF

6. Evolution of Rituximab as “Standard” Therapy in Patients (pts) with Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL) in Japan: An Analysis from West-Japan Hematology/Oncology Group (West-JHOG) NHL Outcomes Project.

Author

Nawa, Yuichiro, Matsuo, Keitaro, Sunami, Kazuki, Togitani, Kazuto, Takimoto, Hidetaka, Nishimori, Hisakazu, Maeda, Yoshinobu, Hiramatsu, Yasushi, Kiguchi, Toru, Yano, Tomofumi, Yamane, Hiromichi, Tabayashi, Takayuki, Takeuchi, Makoto, Makita, Masanori, Sezaki, Nobuo, Ikeda, Kazuma, Ishimaru, Fumihiko, Shinagawa, Katsuji, Hara, Masamichi, and Tanimoto, Mitsune

Published
2006
Full Text
View/download PDF

7. Prevalent hyper-methylation of the CDH13 gene promoter in malignant B cell lymphomas.

Author

Ogama Y, Ouchida M, Yoshino T, Ito S, Takimoto H, Shiote Y, Ishimaru F, Harada M, Tanimoto M, and Shimizu K

Subjects
Azacitidine pharmacology, Cadherins metabolism, Cell Line, Tumor, CpG Islands genetics, Decitabine, Gene Expression drug effects, Humans, Lymphoma, B-Cell diagnosis, Lymphoma, B-Cell metabolism, Lymphoma, Large B-Cell, Diffuse diagnosis, Lymphoma, Large B-Cell, Diffuse metabolism, Prognosis, RNA, Messenger analysis, RNA, Messenger metabolism, Azacitidine analogs & derivatives, Cadherins genetics, DNA Methylation, Lymphoma, B-Cell genetics, Lymphoma, Large B-Cell, Diffuse genetics, Promoter Regions, Genetic
Abstract

CDH13 (H-cadherin) is a member of the cadherin superfamily, which plays an important role in cell recognition and adhesion. We examined the expression and methylation status of the CDH13 gene in diffuse large B cell lymphomas (B-DLCLs). We found decreased expression of the CDH13 gene in all of 6 hematopoietic cell lines by reverse transcription-polymerase chain reaction (RT-PCR). Promoter hyper-methylation of the gene was detected in all 6 cell lines and in 13 of 19 (68%) B-DLCL samples by methylation-specific PCR. Interestingly, the methylation frequency of the CDH13 gene was comparable to those of the tumor suppressor genes p15 (68%) and p16 (74%) detected in B-DLCLs. Sequencing of bisulfite-treated DNA revealed hyper-methylation of the CpG islands of the CDH13 promoter in B-DLCLs and the cell lines. Treatment with 5-aza-2'-deoxycytidine restored CDH13 gene expression in a cell line in which promoter hyper-methylation and impaired expression of the CDH13 gene were observed. Loss of heterozygosity (LOH) around the CDH13 gene on chromosome 16q24 was detected in 6 of 15 (40%) informative cases with microsatellite marker D16S507 and in 6 of 15 (40%) cases with D16S422 in B-DLCLs. In all of 4 B-DLCL cases which showed both promoter methylation and LOH at the two marker loci, expression of the CDH13 gene was significantly low. These results suggest that silencing of the CDH13 gene by aberrant promoter methylation and allelic deletion is associated with tumorigenesis in a subset of B-DLCL.

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results